Previous 10 | Next 10 |
2023-05-12 17:45:30 ET Gainers: GSI Technology ( GSIT ) +16% . Telos ( TLS ) +8% . Arcturus Therapeutics Holdings ( ARCT ) +5% . Atara Biotherapeutics ( ATRA ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Zapp Electric Ve...
2023-05-11 19:10:07 ET Summary Results from the phase 2 BOLD study, using ATA188 for the treatment of patients with progressive multiple sclerosis, are expected in October of 2023. It is said that the global multiple sclerosis drug market size could reach $34.03 billion by 2031; A...
2023-05-08 18:03:40 ET Gainers: Oportun Financial ( OPRT ) +23% . EverQuote ( EVER ) +22% . Tactile Systems Technology ( TCMD ) +17% . Rover Group ( ROVR ) +14% . Y-mAbs Therapeutics ( YMAB ) +13% . Losers: Enanta P...
2023-05-08 17:07:02 ET Atara Biotherapeutics press release ( NASDAQ: ATRA ): Q1 GAAP EPS of -$0.72 misses by $0.36 . Revenue of $1.23M (-83.2% Y/Y) misses by $29.45M . Cash, cash equivalents and short-term investments as of March 31, 2023, totaled $205.4 millio...
First Patients Treated in Europe with EBVALLO TM Following Transfer of EC Marketing Authorization to Pierre Fabre; Discussions with FDA Progressing ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023 ATA3219 IND Filing Anticipated End of Q2 2023 ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 202...
2023-04-16 12:08:24 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky. If they fail, their stocks can languish a...
2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 62,350 restricted stock units ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...